FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
December 23, 2025 • 1m 26s
Carl Quintanilla (Anchor)
00:00.740
welcome
back
novo
nordisk
gaining
FDA
approval
for
the
first
oral
weight
loss
drug
our
annika
constantino
spoke
with
the
CEO
and
joins
us
this
morning
hey
annika
Annika Kim Constantino (Health and Science Reporter)
00:10.800
hi
carl
that's
right
so
we're
all
familiar
with
novo
's
blockbuster
weekly
injection
wegovy
but
for
the
very
first
time
patients
will
be
able
to
access
an
oral
version
of
that
drug
it's
the
first
ever
GLP
one
pill
specifically
approved
for
obesity
and
it's
launching
early
in
Annika Kim Constantino (Health and Science Reporter)
00:25.520
twenty
twenty
six
and
novo
says
it's
priced
at
a
significant
discount
to
what
we've
seen
with
existing
injections
at
roughly
a
hundred
fifty
dollars
per
month
before
insurance
for
the
starting
doses
and
first
and
foremost
this
approval
is
really
important
for
patients
giving
Annika Kim Constantino (Health and Science Reporter)
00:39.520
them
additional
treatment
options
here
and
early
this
morning
i
spoke
with
novo
CEO
mike
dude
star
and
here's
what
he
said
about
how
this
could
expand
obesity
treatment
access
in
the
US
Mike Doustdar (President and CEO)
00:50.990
i
believe
that
this
will
quite
a
bit
expand
the
market
because
because
as
i
mentioned
earlier
you
have
a
situation
where
today
people
are
taking
an
injection
to
reduce
weight
but
we
also
know
from
our
own
family
members
and
circles
of
friends
that
there
are
many
people
who
still
Mike Doustdar (President and CEO)
01:09.030
do
not
rather
take
an
injection
either
because
they're
so
so
much
afraid
of
the
needle
or
their
societal
taboo
that
taking
an
injection
makes
you
feel
sick
and
they
don't
want
to
feel
or
look
sick
for
this
group
of
people
having
a
pill
option
is
very
important
Autoscroll